JSOnline: Madison’s FluGen plans new human trials of universal flu vaccine

Madison biotechnology company FluGen Inc. will start another round of human trials on its universal flu vaccine next year.

The company recently completed a $5.5 million round of funding to support its continuing research and development.

FluGen’s product, RedeeFlu, is a vaccine to prevent the respiratory illness influenza. The idea behind RedeeFlu is to create a universal flu vaccine that will work year after year.

Read the full story here.